Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 1/20 | 0.73 |
| ▸ | ME1 | P48163 | 1/20 | 0.73 |
| ▸ | ME3 | Q16798 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.53 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972497 | 0.88 | ME2 (0.62) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL8470674 | 0.85 | ME2 (1.00) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL7396868 | 0.82 | ME2 (0.57) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL88986 | 0.81 | CYP1A2 (0.68) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL29779946 | 0.81 | CYP1A2 (0.68) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL8603035 | 0.81 | ME2 (0.56) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL313151 | 0.80 | MEN1 (0.66) | ME2ME1ME3CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL11313207 | 0.80 | CYP1A2 (0.66) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL5380957 | 0.80 | ME2 (0.70) | ME2ME1ME3CYP1A2KDM4E | |
| SCHEMBL5271656 | 0.79 | BID (0.56) | ME2ME1ME3CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008039984-A2 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS BY INHIBITING CATHEPSIN D | OBURA COMPANY (US) | 2008-04-03 | — | — | WO | disclosed |
| US-6407110-B2 | Polyhydroxyalkylpyrazine derivatives and their preparation and medicines containing them | AVENTIS PHARMA S.A. (FR) | 2002-06-18 | — | — | US | disclosed |
| US-20010018439-A1 | Polyhydroxyalkylpyrazine derivatives and their preparation and medicines containing them | AVENTIS PHARMA S.A. (FR) | 2001-08-30 | — | — | US | disclosed |
| EP-0490370-B1 | Electrostatic image-developing toner | MITSUBISHI CHEM CORP (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5200288-A | Mixture of resin, colorant and additive having constant changeability | MITSUBISHI KASEI CORPORATION (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0490370-A1 | Electrostatic image-developing toner | Mitsubishi Chemical Corporation (JP) | 1992-06-17 | — | — | EP | disclosed |
| US-5049574-A | Psychotic diseases | RHONE-POULENC SANTE (FR) | 1991-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018439-A1 | Polyhydroxyalkylpyrazine derivatives and their preparation and medicines containing them | CYP11B2, HRH2, NR1H4 | ME2 1616/4885ME1 3464/4885ME3 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.